Scrip spoke with Halozyme CEO Helen Torley, chair of BIO's Workforce Development, Diversity and Inclusion committee, about efforts to communicate the benefits of diverse leadership to CEOs and build a database of diverse board candidates.
BIO's one-year-old Workforce Development, Diversity and Inclusion (WDDI) committee, chaired by Halozyme Therapeutics Inc. CEO Helen Torley, is moving from thought to action in 2018, forging ahead with initiatives in line with its goals for increasing diversity in the biotechnology industry.
The WDDI committee launched a year ago with a set of principles and goals aimed at boosting the participation of...
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
